Tharimmune Inc., a clinical-stage biotechnology company, has announced plans to initiate a first-in-human clinical trial for its promising therapeutic candidate, TH023, within the next 12 months. TH023 is being developed as an innovative oral antibody medication targeting inflammation. This upcoming trial follows positive preclinical results and signifies a significant step in bringing this potential treatment to patients. The company is currently optimizing the formulation and dosing regimen of TH023 in preparation for the trial.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tharimmune Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1055981) on August 04, 2025, and is solely responsible for the information contained therein.